mylan
FDA Approves Fulphila, First Biosimilar to Neulasta
Mylan's Fulphila is the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile ...
JUNE 4, 2018
FDA Approves Simfi Triple Combo HIV Therapy
A new triple combo therapy will be available in the United States that Mylan says will be priced lower than other ...
MARCH 30, 2018
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
Ogivri is the first biosimilar approved in the United States for the treatment of breast cancer or stomach ...
DECEMBER 1, 2017
FDA Approves New Epinephrine Choice for Anaphylaxis
Symjepi is available in a single pack, consisting of one prefilled syringe, or as a two-pack, consisting of two ...
JUNE 19, 2017
FDA Alerts Consumers of Nationwide Voluntary Recall of EpiPen and EpiPen Jr
The auto-injector products, which could contain a defective part, are being recalled because of the potential for ...
APRIL 5, 2017
Mylan Will Pay $465 Million For Medicare/Medicaid EpiPen Rebates
CMS says that Mylan had repeatedly misclassified EpiPen as a generic drug, rather than a branded drug, for ...
OCTOBER 11, 2016